BMRN Stock: Price, Earnings History and SEC Filings
BioMarin Pharmaceutical Inc. (BMRN) last traded at $58.51, up 1.77% on the latest session and down 2.5% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.90 against an analyst estimate of $0.79, a beat of 13.9%.
$58.51 +1.77%
1 month-2.48%
52-week high$70.98
52-week low$49.26
Volume2.27M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BMRN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $0.90 | $0.79 | +13.92% |
| Mar 2026 | May 4, 2026 | $0.58 | $0.78 | -25.64% |
| Dec 2025 | Feb 23, 2026 | $0.28 | $0.07 | +300.00% |
| Sep 2025 | Oct 27, 2025 | $-0.08 | $0.82 | -109.76% |
BMRN beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for BMRN
SEC filing data is not available right now. You can search for BMRN on SEC EDGAR.
BMRN news
- AnaptysBio (ANAB) vs. PTCT and MIRM: Is the Market Missing the Value of Its Royalty Stream and Legal Upside?Oct 31, 2026 · finance.yahoo.com
- Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In DealmakingOct 31, 2026 · stocktwits.com
- Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth?Oct 30, 2026 · finance.yahoo.com
- Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?Oct 29, 2026 · finance.yahoo.com
- BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry DiseaseOct 29, 2026 · finance.yahoo.com
- What Would Slower New Drug Sales Do To Vertex Stock?Oct 28, 2026 · trefis.com
- BioMarin schedules third-quarter results. BioMarin stock is valued at USD 10.7 billionOct 27, 2026 · ad-hoc-news.de
- BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ETOct 26, 2026 · finance.yahoo.com
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. (BMRN) is a US-listed public company on Nasdaq.